Agilent - Breakthroughs in Immunotherapy- 2019 - 38

Breakthroughs in Immunotherapy

Seven hours after addition of effector T cells, cytokines specifically
associated with a CTL response such as IFNγ, TNFα, and IL-2 increased
300-, 9-, and 10-fold, respectively.
Secretion of cytolytic proteins such as sFasL, granzyme B, and perforin
also dramatically increased by 24 hours after the addition of effector
T cells, consistent with the CTL-killing response observed. This data
demonstrates that CD19-BiTE enhances T-cell-mediated B-cell killing by
increasing the production of cytokines and cytolytic proteins essential
for a robust CTL response.

Summary
Here, we have coupled quantitative cell-killing assays with biomarker
quantitation to provide an in-depth view of how CD19-BiTE affects T-cellmediated killing of B cancer cells in a single workflow. The continuous
monitoring of cell number, size, and attachment quality using RTCA
enables quantitative and kinetic assessment of the killing process. Linking
this cytotoxicity data with quantitative analysis of cytokine and effector
protein production allows for simultaneous analysis of T-cell activation and
function. This workflow, which integrates both cellular and protein analyses,
advances current methods for research of cancer immunotherapy. n
Lauren Jachimowicz, PhD, is an application development scientist, Aimee Chiavario is
a senior marketing manager of immuno-oncology, Peifang Ye is a group leader, Garret
Guenther, PhD, and Kenneth Chan, PhD, are product managers, and Jeff Shurong Xue,
PhD, is a director of marketing, at ACEA Biosciences, now a part of Agilent.

38

| GENengnews.com

http://www.GENengnews.com

Agilent - Breakthroughs in Immunotherapy- 2019

Table of Contents for the Digital Edition of Agilent - Breakthroughs in Immunotherapy- 2019